Part 6/9:
They dove into Soros' recent moves, highlighting that he had recently purchased shares in Gilead Sciences and Novavax. Notably, they observed that Soros had shifted towards a biotechnology ETF, the IBB, rather than continuing a focus on individual biotech stocks. This alteration in strategy was interpreted as an acknowledgment of the challenges within the sector, suggesting a defensive stance rather than his usual speculative one.